SAMN03290885
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- MYC_TARGETS_V2+0.400
- ALLOGRAFT_REJECTION+0.300
- APICAL_JUNCTION+0.300
- CHOLESTEROL_HOMEOSTASIS+0.300
- COAGULATION+0.300
- COMPLEMENT+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- INTERFERON_ALPHA_RESPONSE+0.300
Top 10 suppressed
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.400
- MITOTIC_SPINDLE-0.400
- ANDROGEN_RESPONSE-0.300
- MYC_TARGETS_V1-0.200
- PROTEIN_SECRETION-0.200
- UV_RESPONSE_DN-0.200
- BILE_ACID_METABOLISM-0.100
- PEROXISOME-0.100
- SPERMATOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a97448d4-418a-4e9c-bd75-c4d217c20c89 | — | — | 0.908 |
| 2 | MNG1110 | — | — | 0.874 |
| 3 | b2b53efa-8a7b-4871-b6bb-6ebfb5cc0cea | — | — | 0.870 |
| 4 | BS_HZRM07TW | Med | Medulloblastoma | 0.860 |
| 5 | 131e315e-6653-4199-b653-42b81644dad9 | — | — | 0.846 |
| 6 | BS_W7FP2G3F | DNET | — | 0.844 |
| 7 | 966a66a2-8aac-41e8-8007-88fd92d2e8e8 | — | — | 0.844 |
| 8 | SRR3147740 | — | — | 0.842 |
| 9 | SRR3147742 | — | — | 0.837 |
| 10 | b9189c77-004e-461a-9c15-b504b12a3030 | — | — | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |